Update 438 on the use of immunoglobulin in human disease: A review of evidence ,
, Allergy Clin Immunol, vol.139, pp.1-46, 2017.
Intravenous immune globulin in autoimmune and inflammatory 441 diseases, N Engl J Med, vol.367, pp.2015-2040, 2012. ,
Intravenous immunoglobulin as clinical 443 immune-modulating therapy, CMAJ, vol.187, pp.257-64, 2015. ,
Intravenous immunoglobulin in 445 neurology--mode of action and clinical efficacy, Nat Rev Neurol, vol.11, pp.80-89, 2015. ,
Intravenous immunoglobulin therapy: how does IgG 447 modulate the immune system?, Nat Rev Immunol, vol.13, pp.176-89, 2013. ,
IVIG-mediated effector functions in 449 autoimmune and inflammatory diseases, Int Immunol, vol.29, pp.491-499, 2017. ,
Basophils: emerging roles in the pathogenesis of allergic disease ,
, Immunol Rev, vol.242, pp.144-60, 2011.
Multifaceted roles of 453 basophils in health and disease, J Allergy Clin Immunol, vol.142, pp.370-80, 2018. ,
Intravenous 455 gammaglobulin suppresses inflammation through a novel T(H)2 pathway ,
, Nature, vol.475, pp.110-113, 2011.
,
, Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory
, M2 phenotype via basophil-derived interleukin-4, Immunity, vol.38, pp.570-80, 2013.
Human 471 basophils may not undergo modulation by DC-SIGN and mannose receptor-472 targeting immunotherapies due to absence of receptors, J Allergy Clin Immunol, vol.473, pp.1403-1407, 2017. ,
,
Expression of CD33-Related siglecs on human eosinophils, basophils and 476 mast Cells, J Allergy Clin Immunol, vol.113, 2004. ,
, Dendritic cell immunoreceptor: a novel receptor for intravenous 479 immunoglobulin mediates induction of regulatory T cells, J Allergy Clin, vol.480, pp.853-63, 2014.
Basophil modulation by cytokine instruction, Eur J Immunol, vol.482, pp.2544-50, 2012. ,
BAFF, a new target for intravenous immunoglobulin in autoimmunity and 607 cancer, J Clin Immunol, vol.27, pp.257-65, 2007. ,
,
, Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in 610 human lymphocytes and monocytes: a novel mechanism of action of IVIg 611 involving the Fas apoptotic pathway, J Immunol, vol.161, pp.3781-90, 1998.
,
, Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic 614 antibodies in the treatment of an experimental murine model of systemic lupus 615 erythematosus, Int Immunol, vol.14, pp.1303-1314, 2002.
,
, Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies
, J Allergy Clin Immunol, vol.119, pp.1005-1016, 2007.
,
, IVIG regulates the survival of human but not mouse neutrophils, Sci Rep, vol.621, p.1296, 2017.
Identification of a 623 receptor required for the anti-inflammatory activity of IVIG, Proc Natl Acad Sci ,
, , vol.105, pp.19571-19579, 2008.
IVIg 626 modulates BCR signaling through CD22 and promotes apoptosis in mature 627 human B lymphocytes, Blood, vol.116, pp.1698-704, 2010. ,
,
, Transcriptional profiling of human dendritic cell populations and models--unique profiles of in vitro dendritic cells and implications on functionality and 631 applicability, PLoS One, vol.8, p.52875, 2013.
,
naturally occurring IgG anti-IgE antibodies may inhibit allergen-634 induced basophil activation, J Allergy Clin Immunol, vol.134, p.636, 2014. ,
Preferential signaling and induction of allergy-promoting 637 lymphokines upon weak stimulation of the high affinity IgE receptor on mast 638 cells, J Exp Med, vol.197, pp.1453-65, 2003. ,
Fc RI-induced 640 activation by low antigen concentrations results in nuclear signals in the 641 absence of degranulation, Mol Immunol, vol.46, pp.2539-2586, 2009. ,
,
, Type I and type II Fc receptors regulate innate and adaptive immunity, Nat 644 Immunol, vol.15, pp.707-723, 2014.
Pathogenesis of chronic urticaria, Clin Exp Allergy, vol.646, pp.777-87, 2009. ,
Effect of Intravenous immunoglobulin in 648 chronic urticaria with increased basophil CD203c expression, J Allergy Clin 649 Immunol, vol.121, p.69, 2008. ,
Inhibition of IgE production in vitro by intact and 651 fragmented intravenous immunoglobulin, J Allergy Clin Immunol, vol.108, p.652, 2001. ,
654 an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation, J Pharmacol Exp Ther, vol.656, pp.998-1008, 2006. ,
, FIG 1. IVIG induces activation and cytokine secretion in IL-3-primed basophils. A-C, 660
, Isolated basophils from the human circulation were cultured either alone or with IVIG. (A 661 and B) Representative dot plots and expression (% positive cells and mean fluorescence 662 intensity (MFI)) of CD69 on the basophils (mean±SEM, n=6 donors). (C) Amount of 663 secretion of IL-4, IL-6 and IL-8 (mean±SEM
Basophils were cultured either alone or with IL-3. IVIG or HSA 665 were added following 2 hours stimulation with IL-3. (D) Representative histogram 666 overlays and MFI of CD69 expression on the basophils (mean±SEM ,
, Representative dot plots and % of basophils (mean±SEM, n=4 donors) positive for CD63, 668 (F) Effect of IVIG on the secretion (pg/ml) of IL-4, IL-6 and IL-8 (mean±SEM, n=12 669 donors
, , p.1
,
0001; ns, 670 not significant, one-way ANOVA with Tukey's multiple comparison tests. G, Expression 671 of CD69 on the basophils of myopathy patients, before (Pre-IVIG) and Post-IVIG therapy ,
, Expression of type II FcRs, Siglecs and C-type lectin receptors on basophils, and 684 the effects of F(ab')2-and Fc-fragments of IVIG on basophil activation, FIG 3, vol.685
, Representative dot plots of CD23 and CD22 expression on the basophils. C and D, p.686
, E-H, Basophils were cultured either alone or with IL-688 3 for 24 hours. IVIG, F(ab')2 or Fc-fragments were added following 2 hours stimulation 689 with IL-3. (E and F) The expression of CD69 (mean±SEM, n=6 donors). (G and H) The 690 amount of secretion of IL-4, Representative dot plots and expression (% positive cells and MFI) of DCIR on the 687 basophils (mean±SEM, n=3 donors)
, , p.1
,
001; ns, not significant, one-way ANOVA with Tukey's multiple ,
A and B, Modulation of Fc?RI expression (Representative 696 histogram overlays and mean±SEM, n=10 donors) in IL-3-primed basophils by IVIG. C, p.697 ,
, Percentage of 698 basophils positive for the surface IgE and its intensity (MFI) (mean±SEM, n=5 donors). E 699 and F, Percentage of basophils positive for IVIG-binding (Representative dot plots and 700 mean±SEM, n=4 donors). G-I, The effect of anti-IgE-reactivity-depleted IVIG on (G, H) 701 the expression of CD69, Representative dot plots showing the basophils positive for surface IgE. D
, and (I) IL-4, and IL-8 secretion (mean±SEM, n=4 donors). *P<0, p.5
, , p.1
,
0001; ns, not significant, two-tailed Mann-Whitney test or one-way 704 ANOVA with Tukey's multiple comparison tests ,
, Activating and inhibitory CD32/Fc?RII are dispensable for the regulation of 707 basophil activation by IVIG. Basophils were cultured either alone or with IL-3 for 24 708 hours. IVIG or HSA were added following 2 hours stimulation with IL-3. A and B, FIG 5, vol.709
, Representative histogram overlays and mean fluorescence intensity (MFI) of expression 710 (mean±SEM, n=8 donors) of Fc?RII and Fc?RIIB on the basophils. C and D, Repercussion 711 of Fc?RIIB blockade on the (C) expression of CD69 and (D) amount of IL
, E and F, Repercussion of Fc?RIIA blockade on the 713 (E) expression of CD69 and (F) amount of IL-4 and IL-8 secretion (mean±SEM, n=4 714 donors
,
,
0001; ns, not significant, one-way 715 ANOVA with Tukey's multiple comparison tests ,
, FIG 6. Inhibition of Syk pathway abrogates IVIG-induced activation of basophils. A and 718
Representative histogram overlays and mean±SEM (n=6 donors) of phosphorylated Syk 719 (pSyk) expression in basophils stimulated with IL-3 or IL-3 plus IVIG. C and D, The 720 effect of Syk inhibition by R406 towards IVIG-induced expression of CD69 721 (Representative histogram overlays and mean±SEM, n=5 donors). E, Syk inhibition 722 abrogates IVIG-induced IL-4, and IL-8 secretion (mean±SEM ,
, , p.1
,
0001; ns, not significant, one-way ANOVA with ,
, Inflammatoires rares et des Amyloses
, Hôpital Pitié-Salpêtrière
, HP
, Sorbonne Paris Cité, Paris, F-75006, France 19 5 Research Department, p.3014
, Immunologie et d'Allergologie; CHU d'Angers; Université d'Angers; INSERM 21 Unité1232; LabEx IGO "Immuno-Graft-Onco
,
, Unit of Antibodies in Therapy and Pathology, 25 List of antibodies for flow cytometry and functional assays
, Clone:H5C6), CD13-APC (Clone:WM15), p.69
, Clone:FN50), CD209-APC (Clone:DCN46)
, Clone:DREG-56) were from BD Biosciences. Fc?RI?-FITC (Clone:CRA-1)
, Clone:REA214), SIGLEC8-APC (Clone:7C9), anti-IgE-APC (clone:MB10-5C4) MAbs 56 were obtained from Miltenyi Biotec. CD203c-PE (Clone:NP4D6), p.23
, Clone:9E8) MAbs were from BioLegend. Anti-IgE MAb (Clone:GE-1) was from Sigma
Unconjugated and FITC-labelled Fc?RIIA MAb (Clone:IV.3) was purchased from ,
, Stem Cells Technologies. Human ST2/IL-33R-PE polyclonal goat IgG and Isotype control
, Anti-hFc?RIIB (Clone:2B6 variant N297D) MAbs 63 were coupled to Alexa Fluor 647 by using ThermoFisher Scientific kit and IVIG was labelled 64 with the Lightning-Link® Rapid DyLight® 650 kit, MAbs for blocking experiments were from R&D Systems